Introduction
Despite mass-immunization campaigns with the parenterally administrated attenuated vaccine strain, measles remains a major cause of infant mortality in the Third WorId. During the first year of life, incidence of measles can be as high as 30 to 50% in certain developing countries. However, the vaccination efficiency in such young children is reduced by the presence of maternal antibodies (Albrecht et al., 1977; Bloom, 1989) . Attempts to overcome this difficulty by administering high-titre attenuated vaccines resulted in increased mortality (Garenne & Leroy, 1991) , suggesting the need to develop new strategies for measles vaccination.
Recombinant vaccinia viruses expressing individual measles virus (MV) proteins have been developed, and proven to be highly immunogenic in mice after parenteral administration Author for correspondence: Dominique Kaiserlian.
Fax + 33 72 72 25 67, e-mail fwipaly@imaginet.fr (Beauverger el al., 1993 b; Drillien et al., 1988; Wild et al., 1992 Wild et al., , 1993 . This anti-measles immunity included circulating antibodies and class I-restricted cytotoxic T lymphocytes (CTL) in the spleen, resulting in protection from MV encephalitis. Nevertheless, although the passive transfer of anti-MV antibodies in mice did not affect the CTL response to vaccinia virus-measles virus recombinants (VV-MV), anti-MV antibody production was suppressed (Galletti et al., 1995) . Previous studies showed that mucosally administered, aerosolized measles vaccine was immunogenic in infants even in the presence of maternal antibodies (Sabin et al., 1983) . Furthermore, in a mouse model, it was shown that VV recombinants expressing respiratory syncytial virus (RSV) genes interfered less with passively acquired antibodies when administered by the nasal route (Murphy et al., 1989) .
Mucosal immunization has the advantage of eliciting a specific immune response on mucosae, which is the entry site of most pathogens. This immune response is mainly secretory IgA, and is capable of antigen neutralization in the lumen of the mucosae. Recent studies have shown that IgA in its polymeric form can also neutralize viruses inside infected epithelial cells during their transcytosis. Furthermore, it appears that polymeric IgA can also bind to the pathogen in the lamina propria, which allows elimination of the virus by the secretory pathway (Mazanec et al., 1992) . In the case of measles, the respiratory tract is the primary entry site of the virus, but MV-associated pathologies can occur on all mucosae, including the intestine. In this respect, a cytopathic effect of MV on human intestinal mucosa has been reported to result in diarrhoea and realabsorption (Jirapinyo et al., 1990) . Thus, it would be beneficial that MV vaccines induce specific immunity in both the lung and the intestine. According to the notion of a common mucosal immune system (McDermott & Bienenstock, 1979; Czerkinsky et al., 1987) , this could be achieved by oral immunization.
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The aim of the present study was to analyse the efficiency of mucosal immunization as compared to parenteral immunization with a VV recombinant vector expressing the MV haemagglutinin (HA) gene. The HA protein is responsible for attachment of the virus to the host cell. Mucosal immunizations consisted of nasal-, oral-or intraintestinal administrations of W-HA. Mucosal and systemic anti-HA antibody-producing cells as well as the class I-restricted, HAspecific CTL response were investigated. Cholera toxin (CT), a powerful mucosal adjuvant (reviewed in Holmgren et al., 1993) , was tested for its ability to potentiate HA-specific immune responses.
Methods
• Animals. BALB/c (H-2 a) female mice 5 to 8 weeks old were purchased from IFFA-Credo (L'Arbresle, France).
• Viruses. (VV-HA) expressing MV HA (Drillien et al., 1988; Wild et al., 1992 Wild et al., , 1993 , was grown on HeLa cells and titrated on Vero cells. MV Hall6 strain, used as antigen in the ELISPOT assay, was grown and titrated on Vero cells.
• Immunizations. Preliminary experiments were performed to determine the optimal dose and timing of the immunizations, through parenteral as well as mucosal routes. For parenteral immunization, mice were immunized with 106 p.f.u, of VV-HA in 10 lal PBS by tail scarification and boosted 15 days later by intraperitoneal injection of 106 p.f.u. W-HA in 0"2 ml PBS. For the nasa[ immunization, mice, under light ether anaesthesia, were immunized through the nares on days 0, 15 and 25 with 106 p.f.u, of VV-HA alone or in combination with 5 lag of CT (Sigma), in a total volume of 20 lal PBS. For oral immunization, mice were immunized on days 0, 15 and 25 by intragastric intubation of 108 p.f.u, of VV-HA (combined, or not combined, with 10 lag CT), in a total volume of 0"2rot 0"2M-NaHCO s pH8"3. For intrajejunal immunizations, mice under ketamine/xylazine (Sigma) anaesthesia (90 and 20 mg/kg, respectively) underwent laparotomy (1 cm incision). VV-HA (10 s p.f.u, in 100 lal PBS) was injected in the jejunum with a 27-gauge needle. The abdominal muscle wail was closed with resorbable polyglactide suture (Vicryl 4.0, Ethicon, France) and the skin was closed with polyamide suture (Ethicrin 4.0, Ethicon). Three weeks later, the mice received a booster intrajejunaI immunization by the same procedure.
• Isolation of lymphoid cells from spleen, Peyer's patches and mesenteric lymph nodes. Mice were killed by cervical dislocation. Spleen cells used in the ELISPOT assay were prepared by teasing the tissue with needles, and the lymphoid cell suspension was depleted in red blood cells by hypotonic shock in 0"83% ammonium chloride. When used for the CTL assay, the spleen was first perfused with RPMI 1640 medium to remove red blood cells and then teased apart with needles to release lymphoid cells. Peyer's patches and mesenteric lymph node cells were prepared by teasing the tissues through a stainless steel grid.
• Isolation of leukocytes from lung and intestinal tissues.
Pulmonary leukocytes were obtained as previously described (Abraham et al., 1990) . Briefly, the lung was perfused by injecting 5 to I0 ml of chilled (4 °C) Hanks' balanced salt solution (HBSS) into the right ventricle. The lung was then excised, finely minced and incubated for 90 min at 37 °C with agitation in RPMI 1640 containing 5 % fetal calf serum (FCS), 40 U/ml collagenase type VIII (Sigma) and I mg/ml DNase type IV (Sigma). Tissue fragments were removed by rapid filtration on a glass-wool column. Cells were layered onto a gradient consisting of 4 ml of 40% and 4 ml of 72% Percoll in RPMI 1640. After centrifugation at 600 g for 20 min, the cells at the 40-72 % Percoll interface were collected and washed in RPMI 1640. Contamination by epithelial cells was consistently lower than 5 %. The suspension contained approximately 0"3 % of IgA-and 0"I % of IgG-producing cells, as measured by ELISPOT assay.
Leukocytes from gut lamina propria were purified as previously described (Lycke, 1986) . The small intestine was excised, washed several times in HBSS, cut into 1 cm fragments and incubated three times in HBSS containing 10 % FCS and 5 mM-EDTA with constant stirring. The fragments were then incubated for 90 min at 37 °C with agitation in RPMI I640 containing 20% FCS and 40 U/ml collagenase type VIII. Tissue fragments and residual epithelial cells were removed by filtration on a glass-wool column. FinaIly, the leukocytes were collected after centrifugation on a Percol| gradient, as described above for lung leukocytes. The percentage of contaminating epithelial cells varied from 5 to 10 %. The resulting cell suspension contained approximately 40 % IgA and 10 % IgG spot-forming cells (SFC).
The cells were suspended in either RPMI 1640 supplemented with 10% FCS, 100U/ml penicillin, 100lag/ml streptomycin, 4mM-Lg[utamine, 10 mM-HEPES pH 7"0 and 5 x 10 -5 M-fl-mercaptoethanol (complete RPMI 1640) when used for the ELISPOT assay, or in DMEM containing 10% FCS, 80U/ml penicillin, 80 lag/ml streptomycin, 100 lag/ml gentamicin, 4 mM-L-g[utamine, 10 mM-HEPES, 5 x 10 5 M-fl-mercaptoethanol and 2 lag/m[ amphotericin (complete DMEM medium) when used for the CTL assay.
• Measles-specific ELISPOT assay. The number of HA-specific antibody-producing cells present in the spleen, Peyer's patches and lungs was determined on day 5 after the last immunization, using an ELISPOT assay with purified MV as antigen. Briefly, nitrocellulose-bottomed wells of 96-well plates (Millipore) were coated with 100 ~1 of diluted MV (I5 I~g/ml of total proteins) in 0'1 M-sodium carbonate buffer pH 9"6, and incubated overnight at 4 °C. The wells were washed three times with PBS and saturated with RPMI 1640 containing 10 % FCS. Fourfold serial dilutions of 100 ~l of mouse cell suspensions (containing 2 x 10 v, 5 x 106 or 1"25 x 10 G cells/ml) were added to each well and incubated for 15 h at 37 °C. The plates were then washed three times with PBS containing 0"05% Tween 20 (PBS-T), and incubated overnight with biotinconjugated goat anti-mouse IgG or IgA antibody (Sigma) diluted in PBS-T. Unbound antibodies were removed by washing with PBS--T. One-hundred lal of peroxidase-conjugated streptavidin diluted in PBS-T !47~ 
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was added to the wells and incubated for 2 h at room temperature. After further washing with PBS-T, the spots were developed using 3-amino-9-ethylcarbazole (AEC) substrate (Sigma) in citrate buffer pH 5.
• HA-specific CTL assay. HA-specific CTL activity was determined on day 10 after the last immunization, using HA-transfected P815 (H-2 d) target cells (PSI5-HA) and untransfected P815 cells as control (Beauverger et al., 1993 a) , or class I-mismatched EL-4 (H-2~)-HA or Ltk (H-2k)-HA transfectants, according to the previously established protocol (Beauverger et al., 1993 b) . Briefly, lymphocytes from immunized mice (I07 per well) were cultured at 37 °C in 24-well culture plates (Falcon) with mitomycin C (25 pg/ml)-treated P815-HA cells (106 per well) in a total volume of 2 ml of complete DMEM. Five days later, half of the medium was replaced by fresh medium, and the cytotoxic activity was tested on day 7 of culture.
The target cells were radiolabelled by 90 rain incubation at 37 °C with 50 p.Ci Na251CrO4 (sp. act. I Ci/mM) per 106 cells and washed three times in DMEM containing 1% FCS. The target cells (5 x 103 cells/I00 ~tl) were first distributed in 96-well round-bottomed plates, and I00 t~l of various dilutions of lymphocyte suspensions were added to give effector to target (E:T) ratios of I00: i, 30: I, I0:1, 4:1 or 1 : i. After a 5 h incubation, the radioactivity released in the supernatant was determined using a ?-counter (I470 Wizard; Wallac). • Statistical analysis. Analyses were performed using the Student's t-test.
Results

Parenteral immunization with VV-HA induces systemic but not mucosal HA-specific antibody-producing cells
The induction of HA-specific antibody-producing cells after parenteral immunizations with 10 ~ p.f.u, of VV-HA was analysed by the MV-specific ELISPOT assay. HA-specific SFC, predominantly of the IgG isotype (155 -t-95 SFC per 107 cells), and few IgA SFC (21 -I-15 SFC per 107 cells) were found in the spleen of VV-HA immunized mice (Fig. I a) . As expected, the level of specific anti-HA SFC at mucosal sites was either low (lung; Intranasal immunization with VV-HA generates both local and systemic HA-specific antibody-producing cells Nasal immunization with VV-HA (108 p.f.u, per dose) generated anti-HA SFC in the spleen, with comparable levels of IgG and IgA anti-HA-producing cells (Fig. 2 a) . Interestingly, nasal immunization induced high levels of IgA-producing cells in the lung (106+ 15 SFC per 107 cells; Fig. 2b ), whereas the level of IgG SFC in this organ was reminiscent of that found after parenteral immunization (Fig. 2 b) . Since CT is a potent mucosal adjuvant, we investigated whether immunization by the nasal route with VV-HA in the presence of CT could potentiate local and systemic HA-specific SFC responses. The levels of anti-HA SFC in the spleen were greatly enhanced both for IgG (198 4-94 SFC per 10 v cells) and IgA (60 -t-20 SFC per 107 cells) (Fig. 2c ) as compared to those obtained after intranasal immunization with VV-HA alone (P < 0"001 and P < 0"01, respectively). In addition, CT also upregulated HAspecific IgA and IgG SFC in the lung (P < 0"01) (Fig. 2d) . Nasal immunization with VV-HA did not induce any detectable HAspecific SFC in the intestine.
VV-HA induces mucosal HA-specific IgA-producing cells in the intestine after oral immunization only when combined with CT Intragastric administration of 108 p.f.u. VV-HA did not induce HA-specific antibody-producing cells (either of IgG or IgA isotypes), either in the spleen or in the gut (including lamina propria and Peyer's patches). Likewise immunizations with up to 108 p.f.u. VV-HA never induced HA-specific systemic antibody production in the spleen (Fig. 3 a) , although IgA anti-HA SFC could be detected in the lamina propria in some but not all experiments (Fig. 3 b) . In contrast, intragastric co-immunization with 108 p.f.u. VV-HA and CT resulted in a dramatic and reproducible upregulation of anti-HA IgA SFC in the lamina propria (P < 0"02), ranging from 200 to 400 SFC per 10 v cells (Fig. 3d) . No adjuvant effect of CT could be observed in the spleen (Fig. 3 c) . HA-specific SFC were never observed in the lung after oral immunization with 108 p.f.u. W-HA, with or without CT.
HA-specific antibody-producing cells induced by enteric immunization with VV-HA
In order to determine whether the lack of immunogenicity of VV-HA by the oral route was due to virus degradation in the gastrointestinal tract, enteric immunizations were performed by intrajejunal injections of VV-HA in animals under laparotomy. In contrast to intragastric immunization, intrajejunal injection of VV-HA induced both systemic and mucosal HA-specific SFC. HA-specific SFC, predominantly of the IgG subtype, were found in the spleen (Fig. 4a) and in the lung (data not shown) in numbers comparable to those found in the respective organs after parenteral immunization. Moreover, the number of HA-specific IgA SFC in the lamina propria of the gut (720 SFC per 107 cells) was much higher than that induced after oral administration of W-HA with CT (265 SFC per 107 cells; Fig. 4b ) (P < 0"05). As expected, the number of HAspecific IgG SFC in the lamina propria (26 SFC per 107 cells) was consistently lower than that of HA-specific IgA SFC. These data support the hypothesis that VV-HA can be immunogenic in the intestine if protected from gastric degradation. 
HA-specific CTL responses induced by parenteral and mucosal immunizations with VV-HA
HA-specific memory CTL response after parenteral or mucosal immunizations with W -H A was determined by the specific lysis of a stable PSZS-HA transfectant using a CTL assay previously developed in our laboratory (Beauverger et a] ., 1993 b). We first confirmed that this CTL assay allows the detection of HA-specific CTLs with no cross-reactivity to VV antigens. Indeed, CTL activity induced by parenteral or mucosal immunizations with V V -H A was HA-specific, as shown by the specific lysis of P815-HA transfectant but not of either P815-nucleoprotein (NP) or untransfected P815 cells. Negative controls, including mice immunized with VV-NP recombinant or with wild-type VV, never gave rise to CTL activity against P815-HA targets. Furthermore, all CTL responses were MHC class I-restricted since no lysis of class Imismatched EL-4 (H-2b)-HA or Ltk-(H-2k)-HA transfectants was observed (data not shown). Our data confirmed that parenteral immunization with W-HA is able to induce HAspecific class I-restricted CTL of high lyric efficiency reaching up to 60 % cytotoxicity with an E: T ratio as low as 10 to 1 (Fig.  5a ). As previously reported, HA-specific CTL activity was restricted to L a since lysis of P815-HA targets was inhibited by anti-L a but not anti-K a or -D a monoclonal antibodies (Beauverger et al., 1993b (Beauverger et al., , 1994 . Nasal immunization with VV-HA was also able to induce an HA-specific CTL response in the spleen, although of a somewhat lower intensity than that after parenteral immunization (Fig. 5b) . As for parenteral immunization, this CTL activity was inhibited by anti-L a but not anti-K a or -D a monoclonal antibodies, indicating that it was restricted to the L a region (data not shown). Interestingly, intragastric immunization with W-HA induced an anti-HA cytotoxic activity in the spleen (Fig. 5 c) , despite a lack of antibody response. Low levels of HA-specific CTL activity could also be detected in mesenteric lymph node cells of orally immunized mice. However, similar levels of specific CTL activity were also achieved by the nasal or parenteral routes of immunization, suggesting that CTL activity generated in the mesenteric lymph nodes may not be of mucosal origin. We next examined the adjuvant effect of CT on HAspecific CTL responses generated by mucosal immunizations with W-HA. Intranasal immunization with VV-HA in the presence of CT enhanced HA-specific splenic CTL activity as compared to immunization with the VV recombinant alone 30-1 q-14'3 50"9 4-9"5 Intragastric 10-8 ± 6'8 14"5 4-8'5 Enteral 37"9 4-14"2 NT * Dose and timing of immunizations were as described in Methods. HA-specific cytotoxicity was determined by the ~lCr release assay as described in Methods. The results are expressed by subtracting the percentage (background) lysis of untransfected P815 target cells from the percentage lysis of P815-HA transfectant cells at the E:T ratio of 4tol. NT, Not tested.
(P < 0"05). In contrast, addition of CT to the VV recombinant given by the oral route did not affect the level of specific CTL response in the spleen (Table 1) . Finally, enteral immunization by intrajejunal injection of W-HA induced a very high HAspecific CTL activity in the spleen (Fig. 5d) , and also some activity in the mesenteric lymph nodes (not shown).
Discussion
We have investigated MV immunity in mice immunized with a VV recombinant expressing the MV HA. The HA is responsible for attachment of the virus to the host cell receptor CD46 (Naniche et al., 1993) , and is the dominant antigen inducing virus-neutralizing antibodies in man (McFarlin et al., 1980) . Furthermore, passive transfer of HA-specific antibodies can protect mice from MV encephalitis (Giraudon et al., 1985) . In addition, the ability to generate MV-specific class I-restricted cytotoxic T cells seems to correlate with a good prognosis of acute measles infection (Galama eta]., 1978; Niewiesk et al., 1993; Van Binnendijk et al., 1990) . Thus, an efficient mucosal vaccine against MV should be capable of eliciting both HAspecific secretory IgA antibodies at mucosal sites to limit virus entry in the organism, as well as MV-specific CTL to eliminate infected cells.
The VV-HA vector was previously shown to induce a strong anti-HA immune response in mice after parenteral administration (i.e. tail scarification followed by intraperitoneal boost). This included anti-HA IgG antibodies in the serum as well as HA-specific CTLs in the spleen (Drillien et al., 1988; Wild et a]., 1992; Beauverger et al., 1993 b) . Our data confirm these studies, and show high levels of anti-HA SFC (predominantly IgG) and HA-specific CTL in the spleen of mice immunized by the parenteral route. We also observed that parenteral immunization does not elicit anti-HA IgA-producing cells in the lamina propria of the gut, which is consistent with extensive experimental evidence that secretory immunity can only be induced by mucosal routes of immunization (McDermott & Bienenstock, 1979) . The small number of HAspecific IgG-producing cells detected in the lungs of parenterally immunized mice most likely reflects migration through the blood of B cells primed in peripheral lymphoid organs. However, we cannot exclude the possibility that some W-HA may have penetrated through the oropharnyx by auto-or cross-contamination (Meitin & Small, 1993) inasmuch as a few HA-specific IgA-producing cells were also detected in the lungs of these mice.
Intranasal administration of W-HA resulted in the induction of a mucosal immune response, manifested by the presence in the lung of anti-HA antibody-producing cells, mostly of the IgA isotype. Interestingly, immunization via the nasal route also induced a systemic immune response as demonstrated by the presence of both anti-HA SFC and CTL in the spleen. This could be consecutive to virus leakage into the blood circulation by passage through the capillary venules of the highly vascularized nose wall. Furthermore, the fact that splenic HA-specific CTL activity was of similar intensity to that generated after parenteral immunization support this hypothesis. On the other hand, the high numbers of IgA SFC observed in the spleen suggests a mucosal priming of IgAbearing B cells and subsequent migration to the spleen, as reported in previous studies (Burlington et al., 1983) .
CT is a potent mucosal adjuvant both by the nasal and oral routes (Liang et al., 1988; Tamura et al., 1988) . Recent studies showed that a class I-restricted CTL response against ovalbumin could be generated by systemic immunization with the soluble antigen mixed with CT (Bowen et al., 1994) . However, the adjuvant effect of CT on CTL activity after immunization by mucosal routes has not been reported. We investigated whether HA-specific B cell and CTL responses could be potentiated by addition of CT to the vaccine. We first observed that addition of CT to W-HA administered intranasally resulted in a 2-to 3-fold enhancement of HAspecific IgA and IgG-producing cells in the lung and up to a I0-fold increase in systemic specific IgG SFC. It appeared that HAspecific CTL activity in the spleen was also upregulated in the presence of CT (P < 0"05).
Our results are consistent with the idea that intranasal immunization with live recombinant viruses expressing foreign antigens can elicit both mucosal and systemic antibody responses as well as a CTL response, and so may serve to provide maximum protection at the site of initial infection with MV or other respiratory viruses (Gallichan et al., 1993; Kulkarni et a]., 1993; Lawson et al., 1994; Meitin et al., 1991) . CT can increase the efficiency of immunization with W-HA. However, due to the toxicity of the whole CT, it will be necessary to re-investigate using the non-toxic B-subunit of CT.
Oral (intragastric) immunization with VV-HA at doses up to I0 s p.f.u, failed to induce any systemic humoral immune response. However, a mucosal anti-HA IgA response was observed in the lamina propria of the intestine, although its magnitude varied greatly between experiments and/or individual mice. In contrast, all the mice showed HA-specific CTL activity in the spleen, indicating that oral immunization with recombinant W vectors is able to generate systemic cellmediated immunity. This finding further confirms previous observations made with a recombinant VV vector expressing rotavirus genes (Offit eta] ., 1994). Co-administration of W-HA and CT by the oral route induced a dramatic increase in the number of HA-specific IgA SFC in the lamina propria of the intestine. At variance with the intranasal route, the adjuvant effect of CT administered orally did not affect the systemic HA-specific antibody and CTL responses. These differing effects of CT may be due to the great sensitivity of the W vector to degradation in the gastrointestinal tract. Thus, adjuvancy of CT may only be efficient in enhancing the capture of a few intact W-HA particles and its transport through the gut epithelium, inducing a local immune response. Interestingly, the strong HA-specific B cell response, associated with high levels of class I-restricted CTL activity in the spleen observed after intrajejunal injection of W-HA, confirms previous data obtained by enteric immunization with a VV vector expressing the HA protein of infleunza virus (Meitin et al., 1994) , and supports the idea that the VV is very sensitive to gastric degradation. This also indicates that oral !47 immunization with encapsulated VV-HA may be a way to prevent virus degradation and to improve its immunogenicity.
Our data show that mucosal immunization with VV-HA generates measles-specific mucosal IgA and systemic CTL responses. Intranasal immunization induces measles-specific IgA in the lung, which is the primary site of MV replication. Furthermore, oral immunization can induce measles-specific IgA in the intestine provided that CT is used as adjuvant. Together, these data support the idea that a mucosal vaccine against measles may allow protection both at the primary site of virus replication (lungs) and at distinct mucosae (intestine) involved in disease complications (Jirapinyo e~ al., 1990) .
